Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025
CEO Amir Reichman to meet investors, pharma partners, and CDMO clients at global biotech conference
JERUSALEM, June 12, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company developing inflammation and immunology (I&I) therapies and offering biologics CDMO services through its Scinai BioServices unit, today announced CEO Amir Reichman's participation in the BIO International Convention 2025 (June 16–19, Boston). The company will leverage the event to showcase its recent financial, operational, and strategic advances to prospective partners and investors.
Recent SEPA Funding Enhances Operational Flexibility
Last week, Scinai raised $1.38 million in gross proceeds through drawdowns under its Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors. The funding was executed at a volume-weighted average price of approximately $3.03 per ADS, reflecting a 3% discount to market, and was completed without any warrants, fees, or additional dilution mechanisms. The proceeds strengthen Scinai's balance sheet and provide additional capital to advance both its CDMO growth and R&D programs. The company is now accelerating supplier and partner engagements in order to advance its nanobody pipeline toward IND-enabling studies, while simultaneously working to expand CDMO capacity and marketing outreach.
CDMO Business Scales Rapidly; 2025 Revenue Expected to Reach $2M
Scinai's Q1 2025 financial results, released last month, showed rapid growth in CDMO revenues, nearly matching full-year 2024 revenues in just the first quarter. Based on strong demand and capacity utilization, the company has issued 2025 revenue guidance of approximately $2 million. Scinai currently anticipates its CDMO unit will reach breakeven by end of 2026, with long-term revenue potential of $12 million annually under a single production shift, scalable further with additional shifts.
Cost Optimization Reduces Burn, Extends Runway, and Enhances Financial Stability
Scinai recently implemented a targeted cost-reduction program expected to lower annual employment-related expenses by approximately $815,000. The initiative is aimed at reducing the company's operational burn rate, extending its financial runway, and improving overall financial resilience—while preserving the core scientific and operational talent critical to executing its CDMO and therapeutic development strategies.
CEO Commentary and BIO 2025 Objectives
"We're heading into BIO with momentum on all fronts, new funding, commercial traction in our CDMO business, and focused execution across our R&D programs," said Amir Reichman, CEO of Scinai. "We're proud of the progress we've made and are eager to explore new collaborations with pharma partners, CDMO clients, and investors."
At BIO 2025, Mr. Reichman will hold meetings with pharmaceutical executives, institutional investors, and CDMO customers to present Scinai's recent achievements and discuss upcoming partnership opportunities.
For meeting requests, please contact Scinai through the BIO partnering system or at info@scinai.com
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (nanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing biological drug development, analytical methods development, clinical cGMP manufacturing, and pre-clinical and clinical trial design and execution services for early stage biotech drug development projects.
Company website: www.scinai.com
Company Contacts
Investor Relations - Allele Capital Partners | +1 978 857 5075 | aeriksen@allelecapital.com
Business Development | +972 8 930 2529 | bd@scinai.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to; the risk that the Company will not be successful in advancing its CDMO growth or R&D programs; that the Company's CDMO will not reach breakeven by the end of 2026, or at all, or that long-term revenues of the CDMO unit will not increase as currently anticipated; the risk that the Company will be unable to remain compliant with the continued listing requirements of Nasdaq; lower than anticipated revenues of Scinai's CDMO business in 2025 and thereafter; failure to sign agreements with other potential clients of the CDMO business; a delay in the commencement and results of pre-clinical and clinical studies, including the Phase 1/2a study for psoriasis, the risk of delay in, Scinai's inability to conduct, or the unsuccessful results of, its research and development activities, including the contemplated in-vivo studies and a clinical trial; the risk that Scinai will not be successful in expanding its CDMO business or in-license other nanoAbs; the risk that Scinai may not be able to secure additional capital on attractive terms, if at all; the risk that the therapeutic and commercial potential of nanoAbs will not be met or that Scinai will not be successful in bringing the nanoAbs towards commercialization; the risk of a delay in the preclinical and clinical trials data for nanoAbs, if any; the risk that our business strategy may not be successful; Scinai's ability to acquire rights to additional product opportunities; Scinai's ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory approval of Scinai's manufacturing facility in Jerusalem, if at all or when required; and the risk that drug development involves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC") on May 7, 2025, and the Company's subsequent filings with the SEC. Scinai undertakes no obligation to revise or update any forward-looking statement for any reason.
Logo: https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/scinai-highlights-new-funding-and-cdmo-growth-ahead-of-bio-international-convention-2025-302480183.html
SOURCE Scinai Immunotherapeutics Ltd.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Corner Bakery Cafe® Brings Fresh Flavors to Irvine with Grand Opening of New Location
IRVINE, Calif., June 13, 2025 /PRNewswire/ -- Corner Bakery Cafe® is excited to announce the grand opening of its newest Southern California location at 13652 Jamboree Rd. in the heart of Irvine on Monday, June 16. This marks the brand's 30th location in California, bringing its signature made-to-order breakfasts, gourmet sandwiches, savory soups, and handcrafted salads to one of Orange County's most vibrant and fast-growing communities. To celebrate the grand opening, the first 100 guests in line will receive a branded Corner Bakery travel tumbler along with free coffee refills for a year, the perfect way to fuel busy mornings in this bustling city. Opening-day guests will also have the chance to enter an exclusive raffle for their choice of Free Paninis for a Year or a Free Corner Classic Order for a future gathering. The raffle winner will be selected the next day and contacted by a member of the Corner Bakery Catering Team to select their prize. Adding to the festivities, a live DJ will be spinning throughout the day, and guests can try their luck at the Spin the Wheel station for a chance to win free Corner Bakery coupons and prizes—making this a true community celebration. "Irvine is an exciting, fast-growing market that aligns perfectly with the Corner Bakery experience—offering fresh, craveable menu items in a warm, welcoming atmosphere," said Erin Hasselgren, president of Corner Bakery Cafe. "We are thrilled to open our doors and look forward to becoming a favorite neighborhood spot." A great alternative to fast food fare, Corner Bakery Cafe offers guests an elevated café experience rooted in quality, comfort, and convenience. The Irvine opening marks a continuation of Corner Bakery's national investment in corporate café expansion. It joins recent openings at Union Station in Chicago and Capitol Hill in Washington, D.C., as well as the highly anticipated re-opening of the Accenture Tower location in Chicago. These strategic moves underscore the brand's commitment to growth and revitalization across key U.S. markets. With its newest café in Irvine set to officially welcome guests, Corner Bakery Cafe continues to deliver on its promise of thoughtfully prepared food served in a welcoming neighborhood atmosphere—an ideal destination for breakfast meetups, coffee breaks, working lunches, or catered events. Following the grand opening, the Irvine Corner Bakery Cafe will operate seven days a week from 7:00 a.m. to 9:00 p.m. For more information, visit or follow Corner Bakery CafeⓇ on Facebook, Instagram, LinkedIn or TikTok. *Pricing and availability vary by location. ABOUT CORNER BAKERY CAFE Corner Bakery Cafe is a fast-casual restaurant serving kitchen-crafted breakfast, lunch, dinner and catering to guests in 18 states and Washington, D.C. In 1991, inspired by great fresh ingredients, the small neighborhood bakery on a corner in downtown Chicago began creating artisan breads and freshly baked sweets. For the last 33 years, Corner Bakery Cafes have been a neighborhood favorite. Founded on a philosophy of creating a warm and comfortable place for people to relax with friends, family and neighbors, the restaurants feature artisan-inspired, seasonal menu options made with fresh ingredients, while delivering a premier bakery experience in the heart of neighborhoods across the nation. Guests' favorites include the crave-worthy Anaheim Scrambler for breakfast, the grilled-to-perfection Chicken Pomodori Panini for lunch, the kitchen-crafted Pesto Cavatappi pasta for dinner and a slice of rich, flavorful Cinnamon Creme Cake for a sweet treat. The catering menu includes freshly scrambled eggs and Berry & Almond Overnight Oats, baskets of assorted specialty sandwiches, signature pastas and hot and delicious soups. Corner Bakery Cafe is owned by an affiliate of SSCP, a Dallas-based enterprise and an award-winning leader in the restaurant industry. To learn more, visit or follow Corner Bakery CafeⓇ on Facebook, Instagram, LinkedIn or TikTok. View original content to download multimedia: SOURCE Corner Bakery Cafe Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Los Angeles Times
37 minutes ago
- Los Angeles Times
Oil prices leap 7% and US stocks slump more than 1% on worries about the crude market
NEW YORK — Oil prices leaped, and stocks slumped Friday on worries that escalating violence following Israel's attack on Iranian nuclear and military targets could damage the flow of crude around the world, along with the global economy. The Standard & Poor's 500 sank 1.1% and wiped out what had been a modest gain for the week. The Dow Jones Industrial Average dropped 769 points, or 1.8%, and the Nasdaq composite lost 1.3%. The strongest action was in the oil market, where the price of a barrel of benchmark U.S. crude jumped 7.3% to $72.98. Brent crude, the international standard, rose 7% to $74.23 for a barrel. Iran is one of the world's major producers of oil, though sanctions by Western countries have limited its sales. If a wider war erupts, it could slow the flow of Iran's oil to its customers and keep the price of crude and gasoline higher for everyone worldwide. Beyond the oil coming from Iran, analysts also pointed to the potential for disruptions in the Strait of Hormuz, a relatively narrow waterway off Iran's coast. Much of the world's oil that's been pulled from the ground moves through it on ships. Past attacks involving Iran and Israel have seen prices for oil spike initially, only to fall later 'once it became clear that the situation was not escalating and there was no impact on oil supply,' according to Richard Joswick, head of near-term oil at S&P Global Commodity Insights. That has Wall Street waiting to see what will come next. U.S. stock prices dropped to their lowest points for the day after Iran launched ballistic missiles toward Israel. For now, the price of oil has jumped, but it's still lower than it was earlier this year. 'This is an economic shock that nobody really needs, but it is one that seems more like a shock to sentiment than to the fundamentals of the economy,' said Brian Jacobsen, chief economist at Annex Wealth Management. That in turn sent U.S. stocks to a loss that was notable in size but outside their top 15 for the year so far. Companies that use a lot of fuel as part of their business and need their customers feeling confident enough to travel fell to some of the sharpest losses. Cruise operator Carnival dropped 4.9%. United Airlines sank 4.4%, and Norwegian Cruise Line Holdings fell 5%. They helped overshadow gains for U.S. oil producers and other companies that could benefit from increased fighting between Israel and Iran. Exxon Mobil rose 2.2%, and ConocoPhillips gained 2.4% because the leaping price of crude portends bigger profits for them. Contractors that make weapons and defense equipment also rallied. Lockheed Martin, Northrop Grumman and RTX all rose more than 3%. The price of gold climbed as investors searched for safer places to park their cash. An ounce of gold added 1.4%. Often, prices for Treasury bonds will likewise rise when investors are feeling nervous. That's because U.S. government bonds have historically been seen as some of the safest options around. But Treasury prices fell Friday, which in turn pushed up their yields, in part because of worries that a spike in oil prices could drive inflation higher. Inflation has remained relatively tame recently, and it's near the Federal Reserve's target of 2%, but worries are high that it could be set to accelerate because of President Donald Trump's tariffs. That sent the yield on the 10-year Treasury up to 4.41% from 4.36% late Thursday. Higher yields can tug down on prices for stocks and other investments, while making it more expensive for U.S. companies and households to borrow money. A better-than-expected report Friday on sentiment among U.S. consumers also helped drive yields higher. The preliminary report from the University of Michigan said sentiment improved for the first time in six months after Trump put many of his tariffs on pause, while U.S. consumers' expectations for coming inflation eased. On Wall Street, Adobe fell 5.3% even though the company behind Photoshop reported a stronger profit for the latest quarter than Wall Street expected. Analysts called it a solid performance but said investors may have been looking for some bigger revenue forecasts for the upcoming year. Shares of Brazilian meat giant JBS fell 3.9% as they made their debut on the New York Stock Exchange. The company wants to increase access to its shares among global investors, despite criticism from environmental groups, U.S. lawmakers and others who noted JBS' record of corruption, monopolistic behavior and environmental destruction. All told, the S&P 500 fell 68.29 points to 5,976.97. The Dow Jones Industrial Average dropped 769.83 to 42,197.79, and the Nasdaq composite sank 255.66 to 19,406.83. In stock markets abroad, indexes slumped across Europe and Asia. France's CAC 40 lost 1%, and Germany's DAX dropped 1.1% for two of the larger losses. Choe, McHugh and Junzhe write for the Associated Press.
Yahoo
an hour ago
- Yahoo
Chegg, Victoria's Secret, Blink Charging, Applied Digital, and Peloton Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the major indices pulled back (Nasdaq -1.3%, S&P 500 -1.1%) as Israel carried out significant strikes on Iranian nuclear and military sites, dramatically escalating fears of a broader conflict in the Middle East. This development has sent crude oil prices surging, as investors fear potential disruptions to global oil supply and a wider regional conflict. The conflict intensified market anxiety, compounding volatility, especially in risk assets like stocks, and prompting a pronounced shift toward safe-haven assets. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Consumer Subscription company Chegg (NYSE:CHGG) fell 7.1%. Is now the time to buy Chegg? Access our full analysis report here, it's free. Apparel Retailer company Victoria's Secret (NYSE:VSCO) fell 6.4%. Is now the time to buy Victoria's Secret? Access our full analysis report here, it's free. Renewable Energy company Blink Charging (NASDAQ:BLNK) fell 6.3%. Is now the time to buy Blink Charging? Access our full analysis report here, it's free. Enterprise Networking company Applied Digital (NASDAQ:APLD) fell 9.9%. Is now the time to buy Applied Digital? Access our full analysis report here, it's free. Consumer Electronics company Peloton (NASDAQ:PTON) fell 5.4%. Is now the time to buy Peloton? Access our full analysis report here, it's free. Applied Digital's shares are extremely volatile and have had 115 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 11 days ago when the stock gained 51% on the news that it signed two long-term lease agreements for artificial intelligence data centers with Nvidia-backed AI hyperscaler CoreWeave. APLD is expected to deliver 250 megawatts (MW) of power for CoreWeave's AI and high-performance computing (HPC) infrastructure at its North Dakota data center campus. The bigger takeaway is financial: across the 15-year term, these contracts are expected to generate about $7 billion in revenue, providing significant long-term financial visibility for Applied Digital. The stock's reaction suggested investors viewed the deals as both a reliable new stream of recurring income and a clear signal that Applied Digital is well positioned in the rapidly expanding AI-data-center space. Applied Digital is up 43.3% since the beginning of the year, but at $11.18 per share, it is still trading 19.4% below its 52-week high of $13.86 from June 2025. Investors who bought $1,000 worth of Applied Digital's shares 5 years ago would now be looking at an investment worth $124,196. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
